{"filing":{"accession_number":"0001999371-26-013527","cik":"0000842023","ticker":"TECH","company_name":"BIO-TECHNE Corp","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tech-8k_062326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013527/tech-8k_062326.htm"},"events":[{"id":14059,"run_id":12499,"accession_number":"0001999371-26-013527","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Bio-Techne Corporation entered into an Agreement and Plan of Merger with Merck KGaA and its subsidiary EMD Holdings NewCo, Inc., whereby Bio-Techne will merge with and become a wholly-owned subsidiary of Merck for $73.00 per share in cash. This is a material acquisition and change of control transaction.","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11387,"accession_number":"0001999371-26-013527","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Bio-Techne Corporation entered into an Agreement and Plan of Merger with Merck KGaA and its subsidiary EMD Holdings NewCo, Inc., whereby the Company will merge with and become a wholly-owned subsidiary of Merck for $73.00 per share in cash. This is a material acquisition/change of control transaction requiring shareholder approval, disclosed under Item 1.01 (Entry into a Material Definitive Agreement).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:03:59.158336+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":14060,"run_id":12499,"accession_number":"0001999371-26-013527","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Compensation Committee approved cash retention bonus awards to named executive officers (Kim Kelderman, Jim Hippel, William Geist, Shane Bohnen, and Steve Crouse) totaling approximately $6.7 million, contingent on the contemplated Merger, including associated tax gross-up provisions.","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11388,"accession_number":"0001999371-26-013527","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved cash retention bonus awards to named executive officers (Kim Kelderman, Jim Hippel, William Geist, Shane Bohnen, and Steve Crouse) totaling approximately $6.7 million, contingent on the contemplated Merger. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The retention bonuses and associated tax gross-up provisions are material to investors evaluating executive incentives in the context of a merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:03:59.158336+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11387,"accession_number":"0001999371-26-013527","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Bio-Techne Corporation entered into an Agreement and Plan of Merger with Merck KGaA and its subsidiary EMD Holdings NewCo, Inc., whereby the Company will merge with and become a wholly-owned subsidiary of Merck for $73.00 per share in cash. This is a material acquisition/change of control transaction requiring shareholder approval, disclosed under Item 1.01 (Entry into a Material Definitive Agreement).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:03:59.158336+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25"},{"id":11388,"accession_number":"0001999371-26-013527","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved cash retention bonus awards to named executive officers (Kim Kelderman, Jim Hippel, William Geist, Shane Bohnen, and Steve Crouse) totaling approximately $6.7 million, contingent on the contemplated Merger. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The retention bonuses and associated tax gross-up provisions are material to investors evaluating executive incentives in the context of a merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:03:59.158336+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25"}]}